A new hypothalamic substance, and not luteinizing hormonereleasing hormone, is detected immunocytochemically by antibody to luteinizing hormone-releasing hormone ( Scharrer, April 13, 1981 ABSTRACT Adjacent paraffin sections of rat hypothalami fixed in Bouin's fluid were treated either with buffer or with luteinizing hormone-releasing hormone (LHRH) before immunocytochemical staining with anti-LHRH. Upon buffer pretreatment, pituitary gonadotrophs were unstained and hypothalamic fibers were stained. Upon LHRH pretreatment, pituitary gonadotrophs were stained (receptor reaction) and hypothalamic fibers were unstained. Extension of washes and use of series of neutralizing antisera between LHRH application and immunocytochemical staining, as well as the absence of inhibiting concentrations of LHRH in the later washes and neutralizing antisera removed from the sections, excluded the possibility that the disappearance of visualization of hypothalamic fibers was due to blockage of anti-LHRH in immunocytochemical staining. The results suggested that LHRH removed from the sections an immunocytochemically stainable but as yet unknown analog of LHRH and replaced it with LHRH, which in turn became lost during subsequent immunocytochemical processing. This idea was confirmed by the isolation by high-pressure liquid chromatography of a peak, distinct from LHRH, upon treatment of hypothalami with LHRH. It is suggested that the new substance may be carrierheld and that this substance, rather than LHRH, is normally detected by immunocytochemistry with anti-LHRH. Added LHRH binds not only to high-affinity pituitary receptors but also to lowaffinity hypothalamic carriers. Projections presumed to contain the decapeptide luteinizing hormone-releasing hormone (LHRH) are revealed by immunocytochemistry with anti-LHRH over wide areas in the brain (for review, see ref. 1). Visualization ofLHRH in Vibratome and even paraffin sections of fixed tissue is surprising because the decapeptide possesses no primary amine that is readily reactive with common aldehyde fixatives. Also, LHRH is highly soluble in water and in the alcohols used during fixation, embedding, and immunocytochemical staining.
In work intended to reveal LHRH receptors not only in the pituitary (2, 3) but also in the rest ofthe brain, we treated parasagittal sections of Bouin's fluid-fixed brains with LHRH prior to immunocytochemical processing with anti-LHRH. Adjacent control sections were treated with buffer instead ofLHRH. The control sections revealed the expected fiber staining in the median eminence (ME) and absence of staining in the pituitary. The LHRH-treated sections revealed receptor staining in pituitary gonadotrophs but, despite washing after LHRH treatment, exhibited complete disappearance of staining in the ME.
Two explanations are possible for this unexpected disappearance of fiber staining. Perhaps, a sufficient concentration of added LHRH is held on the section, despite washing, to inhibit the anti-LHRH staining reaction. Alternatively, LHRH proper is never available in fixed, paraffin sections for staining with anti-LHRH. Instead, the factor demonstrated is a LHRH analog that is crossreactive with anti-LHRH and is held in the tissue by a carrier. Treatment with excess LHRH exchanges the analog with LHRH which, because of its high solubility, is lost during subsequent immunocytochemical processing.
In the present study, we attempted to distinguish between the two possibilities by extending the washing procedure after application of LHRH and by treating sections repeatedly with anti-LHRH prior to staining, to neutralize any remaining LHRH in the section. In addition, we analyzed washes and neutralizing antisera for the presence of LHRH in concentrations sufficient to inhibit immunocytochemical staining. On the basis ofthese experiments we concluded that, indeed, the factor staining with anti-LHRH is removed from the sections by LHRH pretreatment. The data suggested an isolation procedure for this factor, and its identification by high-pressure liquid chromatography (HPLC) is reported.
MATERIALS AND METHODS
Male Sprague-Dawley rats were perfused with Bouin's fixative (paraformaldehyde/picric acid/acetic acid), and blocks of hypothalami with attached pituitary were embedded in paraffin. Seven-micrometer-thick serial sections were used for immunocytochemistry. The dissected hypothalami (with or without pituitaries) and cerebella of eight other perfused rats were brought through two changes of50% ethanol for 1 hr each, three changes of 70% ethanol for a total of 20 hr, and two changes of 95% and 100% ethanol for 1 hr each and then returned to water by reversing the alcohol series. The tissues were then placed in siliconized glass tubes and homogenized with a VirTis homogenizer in 0.5 ml of water or in 0.5 ml of 0.1 mM LHRH, left at 4°C for 24 hr, and centrifuged at 1000 X g at 10C for 60 min. The supernatants were used for HPLC. In addition, those tissues that had been treated with water were extracted a second time with LHRH and the supernates again were used for HPLC.
For immunocytochemical staining, sections were pretreated with LHRH in Tris/saline containing 0.25% human serum albumin (2) Fig. 1) . At 50 AM, LHRH brought about complete abolition of ME staining when volumes of 0.4 ml were used; a small amount ofstaining remained when the volume was 0.05 ml. Use of 1 mM resulted in complete disappearance of staining even with volumes of 0.05 ml.
Experiments to distinguish whether the abolition of ME staining was due to inhibition of anti-LHRH by LHRH carried through the washings to the staining antiserum or, alternatively, to removal of an immunoreactive LHRH analog from the ME by treatment with LHRH included: (i) increases of number of washes after LHRH treatment from three to seven; (ii) increases (Table 1) . Although the first washes at times may have contained LHRH in sufficient concentration to inhibit staining with anti-LHRH (Table 2) , the third washes did not. None of the washes from experiments 4 A and B contained sufficient LHRH to be detected by HPLC. The first neutralizing antiserum contained sufficient LHRH to inhibit staining when obtained from sections pretreated with 0.4 ml of 50 /iM LHRH. The second and third neutralizing antisera were inhibitory only when used at a dilution of 1:1000; they were not inhibitory at 1:100. None of the fourth applications ofantiserum contained sufficient LHRH to neutralize their staining ability. In case ofpretreatment with 0.05 ml of 10 AM LHRH, even the first antiserum failed to contain concentrations of LHRH that inhibited its staining ability for fibers in the ME.
Thus Washes and antisera were transferred onto fresh slides to establish presence of eluted LHRH (see Table 2 ). In addition, washes from Exp. 4 were assayed by HPLC. 1 1 Anti-LHRH was applied to neutralize any LHRH remaining on the section. ** Followed in each case by 3% normal sheep serum for 30 min, anti-LHRH for 24 hr, PAP for 30 min, and diaminobenzidine and H202 for 8 min.
tt LHRH was replaced by buffer.
the final anti-LHRH used for immunocytochemical staining. Furthermore, sections were washed another three times after the final neutralizing antiserum and exposed to 3% normal sheep serum for 30 min prior to immunostaining with anti-LHRH. These results made it unlikely that the ME staining abolition effect was due to inhibition of the final immunostaining anti-LHRH by any LHRH carried through the washing procedure. Lastly, the minimal concentration of LHRH for pituitary receptor staining was found to be 0.1 AM when 0.05-ml applications were followed by extensive washes (experiment 6, Table 1 ), but 0.1 nM when admixed with the staining antiserum. The difference in concentration required for receptor staining shows that the washes were effective in removing most of the LHRH even when bound by high-affinity receptors (3). It would appear, therefore, that the washes certainly would be effective in removing any loosely bound LHRH prior to application of the immunostaining anti-LHRH.
On the basis of these experiments it was thought that the abolition ofME staining was due not to inhibition ofanti-LHRH used in immunostaining but rather to specific removal from the ME of a substance immunostained by anti-LHRH. To confirm this suggestion, LHRH was used as a specific solvent for extraction of this hypothetical substance from hypothalamus. In each of four Bouin's fluid-fixed hypothalami, this procedure eluted a specific peak corresponding to a substance less hydrophobic than LHRH itself (Fig. 2) . No such substance was eluted from four other hypothalami extracted with water instead of LHRH. However, when the water extraction was followed by LHRH, the new peak reappeared. The peak was undetectable when LHRH extracts of cerebella were chromatographed.
DISCUSSION
These experiments show that LHRH removes a specific substance from Bouin-fixed hypothalamus. In the absence of LHRH treatment, this substance is stainable with anti-LHRH by immunocytochemistry. Therefore, staining normally as- Table 1 were reapplied to fresh sections as primary antisera in the PAP procedure to estimate inhibition of staining of fibers in ME. Washes from Table 1 were similarly reapplied after admixture with equal volumes of anti-LHRH (final dilution, 1:1000).
cribed to LHRH is in all likelihood not due to the decapeptide itself but rather to another substance immunologically crossreactive with it. This substance appears to be less hydrophobic than LHRH. Because LHRH itselfis poor in hydrophilic amino acids, it is likely that this new substance possesses amino acids in addition to those found in the decapeptide. However, the substance is not a macromolecule unable to pass through the column used, nor is it of the size and amino acid composition to be irreversibly crosslinked to surrounding tissue during fixation.
It has been shown by Goldsmith and Ganong (6) that more than 98% of LHRH is lost during dehydration of hypothalami in processing for immunocytochemistry. Reanalysis oftheir data suggests, however, that they equally well could have concluded that all, rather than most, LHRH is lost during dehydration. Apparently, they preferred the conclusion that only most of the LHRH is lost to reconcile the fact that they still obtained immunocytochemical staining with anti-LHRH in their processed tissues. The present experiments suggest that all LHRH indeed is lost and that the only substance detectable by immunocytochemistry is an analog more tightly bound to the tissue. We conceive that the bonding is to a carrier through amino acids common to those found in LHRH. This would permit bonding not only of the new substance but also of LHRH to the carrier. The new substance can be exchanged for LHRH, provided that the concentration is high, suggesting that LHRH is bound with lower affinity than the new substance. Once the new substance is displaced by low-affinity-bound LHRH, the LHRH itself is easily lost during washings. It is conceived that the higher affinity of the new substance for the carrier is mediated through its additional amino acids, possibly via dimerization effected by them (1) .
Fixation in Bouin's fixative apparently did not destroy the ability ofthe hypothetical carrier to exchange the new substance for LHRH. This is reminiscent ofthe unique ability ofpicric acid/ paraformaldehyde fixatives to preserve the binding activity of peptide hormone receptors (2, 3, 7) . Furthermore, even in the amine reagent-treated immunoglobulin molecule, the hypervariable regions seemed to be more resistant to destruction of their ability for reaction with antigen than are epitopes in other molecular regions for reaction with second antibody (8, 9) . The use of fixed tissue for elution of the new substance from hypothalamus presumably prevented solubilization of extraneous constituents that could have masked the peak specifically eluted by LHRH. Thus, fixed brain tissue apparently acted as its own affinity medium for purification of the new substance.
There are now available several lines of evidence suggesting the universal importance ofpeptidergic neurons and peripheral endocrine cells (10) in fundamental biologic mechanisms. The early idea of the Scharrers' that predicted this importance was based on the finding of secretory nuclei in the central nervous system of fish outside the hypothalamus and on finding of neuropeptides even in invertebrates (11) . Recent work has confirmed this universality by revealing a number ofneuropeptides with a wide distribution in brain and elsewhere. In addition, considerable heterogeneity of neuropeptide endowment seems I l Neurobiology: Sternberger et al.
to be expressed by the. presence ofseveral neuropeptides in the same cell. Heterogeneity is broad because a given neuropeptide may occur in combinations with sets of different neuropeptides in different cells. Thus, f3-lipotropin and corticotropin (ACTH) and their subunits do not necessarily appear in the same proopiocortin cell (12) . Heterogeneity may be expressed by: the assembly of ACTH in the magnocellular system (13) and. in antral gastrin cells (14) ; differences in. distribution of subunits of proopiocortin in various regions of the hypothalamus (15); Islipotropin immunoreactivity in vasopressin-containing cells (16) and pituitary gonadotrophs (17) ; f3-endorphin-like reactivity in plasma cells (18) ; ACTH immunoreactivity in LHRH nerve terminals (19) ; endorphin in pancreatic. glucagon cells (20) ; and somatostatin coexisting with calcithonin (21) (22) (23) .
We think that this type ofheterogeneity can be explained by the conservative inheritance of neuropeptides which appear with little change in invertebrates (24, 25) and lower (26) and higher vertebrates. Mutations apparently are not easily tolerated in peptides themselves but may occur in nontranscribable regions of the genome. As the locus of excision varies, different transcribable regions of the genome may be ligated to each other, thus explaining-the occurrence of P-lipotropin subunits sometimes within proopiocortin and sometimes with precursors for vasopressin. The resulting permutational heterogeneity may give individual neurons great variability in peptidergic expression (16, 27) .
The findings reported. here seem to reveal another form of heterogeneity. The number of peptides expressed by a cell is increased if it contains other stable, analog forms of a peptide in addition to the form most frequently isolated. The new, presumably carrier-bound, substance may provide such, a different form as far as the LHRH system is concerned. It remains to be established whether this form of LHRH possesses physiologic activity-for instance, differential release offollicle-stimulating and luteinizing hormones in contrast to the indiscriminate release mediated by the decapeptide. Other forms of heterogeneity of the analog type (that is, molecules that may have a precursor-product relationship and thus similar immunoreactivity) have been suggested for LHRH by divergence in staining with different anti-LHRHs (28, 29) and for cholecystokinin (30) , pancreatic polypeptide (31), vasoactive intestinal peptide (32) , and neurophysin (33) by similar staining diversities with respective antisera. Finally, different forms ofthe carboxy-terminal region of P-lipotropin possess opiate activity (34) .
